Mirum Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis
Mirum Pharmaceuticals, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). High-growth rare disease pharmaceutical company with approved commercial portfolio, expanding international presence, and late-stage pipeline expansion poised for sustained revenue acceleration and profitability improvement. Revenue growth of 81% YoY demonstrates strong commercial execution and market traction. Patient identification expansion and international growth are driving margins, while late-stage pipeline programs.
What is Mirum Pharmaceuticals, Inc.'s industry? Mirum Pharmaceuticals, Inc. (mirumpharma.com) operates in Biopharmaceuticals - Rare & Orphan Diseases. AskCyborg classifies Mirum Pharmaceuticals, Inc. under Biopharmaceuticals - Rare & Orphan Diseases in its company registry.
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its commercial portfolio includes LIVMARLI (maralixib...
Cyborg Score thesis
High-growth rare disease pharmaceutical company with approved commercial portfolio, expanding international presence, and...
Read the full analyst-debate transcript →Get the Latest Mirum Pharmaceuticals, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeMirum Pharmaceuticals, Inc. Overview
Pro stress-test →Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome and progressive familial intrahepatic cholestasis, CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis.
Strategic Profile
Pro stress-test →The company achieved 2024 revenue of $336.89 million, representing 80.76% growth compared to prior year. Mirum recently completed the Bluejay Acquisition, expanding its liver disease portfolio. Analysts hold a "Strong Buy" rating with a 12-month price target of $102.64.
Competitive Landscape
Pro stress-test →Mirum competes in the rare disease pharmaceutical space alongside companies like Rhythm Pharmaceuticals, Travere Therapeutics, Tarsus Pharmaceuticals, and AnaptysBio. Mirum's competitive advantage rests on its focused rare disease strategy with multiple approved commercialized products and a late-stage pipeline targeting hepatic and cholestatic disorders.
Industry Context
Mirum Pharmaceuticals, Inc. operates in Biopharmaceuticals - Rare & Orphan Diseases.
Key facts
Founded: 2018 · Headquarters: Foster City, California · Revenue: $336.9M (2024) · Market cap: $5.2B